Peptides > Gonadorelin


Gonadorelin is a hormone agonist that is used for treating infertility and hypogonadism. Recent research suggests potential benefits in slowing the growth of breast and prostate cancer, as well as in the treatment of Alzheimer’s disease.

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.


1. What Is Gonadorelin?


2. Gonadorelin Structure


3. Gonadorelin Effects


4. Gonadorelin Research

What Is Gonadorelin?

Gonadorelin, also known as GnRH, is a decapeptide gonadotropin-releasing hormone agonist. It plays a key role in stimulating the synthesis and release of luteinizing hormone and follicle-stimulating hormone. In human medicine, gonadorelin is used for various purposes, including:

  1. Treatment of Infertility: It is employed to address infertility issues by regulating the reproductive hormone levels.

  2. Management of Menstrual Cycle Irregularities: Gonadorelin can help normalize menstrual cycles in some cases.

  3. Treatment of Hypogonadism: It is used to manage hypogonadism, a condition characterized by insufficient production of sex hormones.

  4. Diagnostic Agent: Gonadorelin is used diagnostically to assess pituitary function.

In addition to these established uses, ongoing research is exploring potential applications of gonadorelin in the treatment of breast and prostate cancer, as well as its potential role in managing Alzheimer’s disease.

Gonadorelin Structure

Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
Molecular Formula: C55H75N17O13
Molecular Weight: 1182.311 g/mol
PubChem CID: 638793
CAS Number: 9034-40-6
Synonyms: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin

Gonadorelin Effects

Gonadorelin, also known as GnRH (Gonadotropin-Releasing Hormone), has shown promise in various aspects of cancer research, particularly in breast and prostate cancer prevention and treatment. Here’s an overview of its potential benefits in these areas:

Breast Cancer Prevention:

  1. Estrogen Suppression: Gonadorelin can suppress the production of estrogen in the ovaries. Since some breast cancer cells rely on estrogen to grow, reducing estrogen levels can be a preventive measure. Women with a higher lifetime exposure to estrogen have a greater risk of breast cancer, and gonadorelin could help reduce this risk.

  2. Risk Reduction: Research suggests that using gonadorelin for an extended period, such as 10 to 15 years, may significantly reduce the risk of breast cancer, potentially by up to 70%. This makes it an attractive and cost-effective option for women at higher risk of developing breast cancer.

  3. Adjuvant Therapy: Gonadorelin can complement the use of anti-estrogen therapies in breast cancer treatment. It can lower overall estrogen levels, making it more difficult for cancer cells to develop resistance to anti-estrogens. This combination therapy could enhance treatment effectiveness and extend its useful lifespan.

Prostate Cancer Treatment:

  1. Hormone Sensitivity: Prostate cancer is highly hormone-sensitive, particularly to testosterone and its derivatives. Gonadorelin effectively cuts off the supply of these hormones to prostate cancer cells.

  2. Medical Castration: Gonadorelin is used as an alternative to surgical removal of the testicles (orchiectomy) in men with aggressive prostate cancer. This medical castration approach has been in use for decades and has shown effectiveness in slowing down cancer growth.

  3. Castration-Resistant Prostate Cancer (CRPC): Some prostate cancer cells can produce androgens locally within the prostate, a phenomenon known as intracrinology. Gonadorelin has contributed to the development of drugs approved by the FDA for treating castration-resistant prostate cancer (CRPC). These drugs offer new options to manage and slow down cancer progression and metastasis.

  4. Combined Androgen Blockade (CAB): Combining gonadorelin with localized drugs in CAB therapy, along with early detection, has shown remarkable results in prostate cancer treatment. It can potentially cure a significant percentage of cases, making it one of the few oncology therapies with curative potential when combined with early detection.

In summary, gonadorelin plays a critical role in hormone-related cancers, particularly breast and prostate cancer. Its ability to suppress estrogen in breast cancer prevention, enhance adjuvant therapy, and treat prostate cancer by reducing androgen levels has made it an essential component of cancer research and treatment. Combined with other therapies and early detection, gonadorelin-based approaches hold significant promise in improving cancer outcomes and even achieving cures in certain cases.


Gonadorelin May Reduce Dementia Risk

Research indicates that sex hormones, particularly leuteinizing hormone (LH), act on the brain in ways that are well outside the scope of sexual dimorphism or reproductive capacity. In fact, the associated rise in LH that occurs with menopause has been correlated with an increased incidence of Alzheimer’s disease and decreased memory performance in both humans and animals. Careful research in rats further reveals that LH acts directly on the hippocampus, the primary memory center in the brain. Rats given LH exhibit decreased memory performance and hippocampus dysfunction, a deficit that is reverse by administration of an LH blocking drug[9].

Further research on LH has revealed that higher levels of the hormone are associated with increased neuropathology. In particular, it has been revealed that LH promotes the development of plaques associated with Alzheimer’s[10]. It stands to reason then that reducing LH levels may help to reduce the progression of Alzheimer’s disease. This has been born out, at least partially, in mouse models showing that getting rid of the LH receptor in the brain improves amyloid pathology and helps to preserve the health of cells like astrocytes, which support and protect neurons[11].

As it turns out, testosterone is beneficial to brain health and actually helps to preserve cognitive function. Thus, simply blocking the entire hypothalamic-pituitary-gondal axis is not necessarily an effective means of treating Alzheimer’s disease. That is why scientists have set out to test gonadorelin derivatives to discern if selective interference in LH production is possible and can have potential benefits. This research, while ongoing, has led to the understanding that leuprolide (a common medication used to treat uterine fibroids and a GnRH receptor agonist) is effective in decreasing the risk of Alzhimer’s compared to other gonadorelin analogues[12]. Ongoing research can help to define why this is the case, but it is important to note that men looking to use highly effective CAB treatment against prostate cancer need not choose between cancer and Alzheimer’s disease. Leuprolide can be used in this setting to offset the risks of CAB with regard to Alzheimer’s disease. In particular, the ability of leuprolide to down-regulate levels of serum gonadotrophins (LH in particular) is generally enough to offset the effects of reduced testosterone[13].

New research is seeking to understand how gonadorelin and its analogues affect APOE and MS4A6A expression in Alzheimer’s disease. Both genetic loci are associated with late-onset Alzheimer’s disease, but research suggests that they need to operate in tandem to produce serious problems and that interfering with one gene loci or the other is enough to short-circuit the pathway to pathology. Gonadorelin affects this process of tandem interaction, but it isn’t clear how or why[14]. Right now, researchers are working to understand how the interaction of genes in Alzheimer’s disease can be interrupted to both treat and prevent the condition. Gonadorelin is am important peptide in that research.

Gonadorelin Research

Gonadorelin is not a new peptide in the realm of human and mammalian disease treatment. However, ongoing research continues to unveil its multifaceted roles in normal physiology and disease development. A significant breakthrough was the discovery that gonadorelin can be used to effectively treat prostate cancer, with a cure rate of up to 99% when detected early. Furthermore, there is growing optimism regarding the potential of gonadorelin and its downstream hormones in understanding and potentially addressing Alzheimer’s disease risk.

It’s important to note that Gonadorelin has minimal side effects, good subcutaneous bioavailability in mice, and is available for research purposes. However, the dosages used in mice do not scale directly to humans. Gonadorelin should only be purchased for educational and scientific research purposes, and it is not intended for human consumption. It is available for sale to licensed researchers.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.